Veterinary Vaccines Market by Type (Porcine, Poultry, Livestock, Companion Animals), Technology (Live Attenuated, Inactivated, Toxoid), Route of Administration (Intramuscular, Subcutaneous, Oral), End User (Hospitals, Clinics) - Global Forecast to 2031

1 INTRODUCTION 35 1.1 STUDY OBJECTIVES 35 1.2 MARKET DEFINITION 36 1.3 STUDY SCOPE 36 1.3.1 MARKETS COVERED & REGIONAL SCOPE 36 1.3.2 INCLUSIONS & EXCLUSIONS 37 1.3.3 YEARS CONSIDERED 38 1.4 CURRENCY CONSIDERED 38 1.5 LIMITATIONS 38 1.6 STAKEHOLDERS 39 1.7 SUMMARY OF CHANGES 39 2 EXECUTIVE SUMMARY 40 2.1 MARKET HIGHLIGHTS & KEY INSIGHTS 40 2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS 41 2.3 DISRUPTIVE TRENDS IN VETERINARY VACCINES MARKET 42 2.4 HIGH-GROWTH SEGMENTS 43 2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST 44 3 PREMIUM INSIGHTS 45 3.1 VETERINARY VACCINES MARKET OVERVIEW 45 3.2 ASIA PACIFIC: VETERINARY VACCINES MARKET, BY COUNTRY AND END USER 46 3.3 GEOGRAPHIC SNAPSHOT OF VETERINARY VACCINES MARKET 47 4 MARKET OVERVIEW 48 4.1 INTRODUCTION 48 4.2 MARKET DYNAMICS 48 4.2.1 DRIVERS 49 4.2.1.1 Increase in companion animal population and pet ownership 49 4.2.1.2 Increasing incidence of infectious and zoonotic diseases 51 4.2.1.3 Favorable initiatives by government agencies and animal health organizations 51 4.2.1.4 Growing demand for animal-derived food products 52 4.2.1.5 Increasing pet insurance penetration and animal health expenditure 54 4.2.2 RESTRAINTS 55 4.2.2.1 High cost of veterinary vaccine development, manufacturing, and cold-chain distribution 55 4.2.3 OPPORTUNITIES 56 4.2.3.1 Advancements in vaccine technologies and strategic collaborations 56 4.2.3.2 Untapped opportunities in emerging livestock and companion animal markets 57 4.2.4 CHALLENGES 57 4.2.4.1 Limited awareness, training gaps, and shortage of veterinary professionals in low-income countries 57 4.2.4.2 Stringent regulatory pathways and complex approval frameworks 58 4.3 UNMET NEEDS & WHITE SPACES 58 4.3.1 UNMET NEEDS IN VETERINARY VACCINES MARKET 58 4.3.2 WHITE SPACE OPPORTUNITIES 59 4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES 60 4.4.1 INTERCONNECTED MARKETS 60 4.4.2 CROSS-SECTOR OPPORTUNITIES 61 4.5 STRATEGIC MOVES BY TIER 1/2/3 PLAYERS 61 4.5.1 STRATEGIC MOVES IN VETERINARY VACCINES MARKET 61 5 INDUSTRY TRENDS 63 5.1 PORTER’S FIVE FORCES ANALYSIS 63 5.1.1 THREAT OF NEW ENTRANTS 64 5.1.2 THREAT OF SUBSTITUTES 64 5.1.3 BARGAINING POWER OF SUPPLIERS 65 5.1.4 BARGAINING POWER OF BUYERS 65 5.1.5 INTENSITY OF COMPETITIVE RIVALRY 65 5.2 MACROECONOMIC INDICATORS 66 5.2.1 INTRODUCTION 66 5.2.2 GDP TRENDS & FORECAST 66 5.2.3 TRENDS IN GLOBAL ANIMAL HEALTH INDUSTRY 67 5.2.4 TRENDS IN GLOBAL VETERINARY BIOLOGICS INDUSTRY 67 5.3 SUPPLY CHAIN ANALYSIS 67 5.4 VALUE CHAIN ANALYSIS 69 5.5 ECOSYSTEM ANALYSIS 70 5.5.1 MANUFACTURERS 71 5.5.2 END USERS 72 5.5.3 REGULATORY BODIES 72 5.6 PRICING ANALYSIS 73 5.6.1 AVERAGE SELLING PRICE TREND OF VETERINARY VACCINES, BY KEY PLAYER, 2023–2025 74 5.6.2 AVERAGE SELLING PRICE TREND OF VETERINARY VACCINES, BY ROUTE OF ADMINISTRATION, 2023–2025 75 5.6.3 AVERAGE SELLING PRICE TREND OF VETERINARY VACCINES, BY END USER, 2023–2025 76 5.6.4 AVERAGE SELLING PRICE TREND OF VETERINARY VACCINES, BY REGION, 2023–2025 77 5.7 TRADE ANALYSIS 77 5.7.1 IMPORT DATA (HS CODE 3002) 78 5.7.2 EXPORT DATA FOR (HS CODE 3002) 78 5.8 REIMBURSEMENT SCENARIO 79 5.9 KEY CONFERENCES & EVENTS, 2026–2027 79 5.10 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 80 5.11 INVESTMENT & FUNDING SCENARIO 81 5.12 CASE STUDY ANALYSIS 82 5.13 IMPACT OF 2025 US TARIFFS ON VETERINARY VACCINES MARKET 83 5.13.1 INTRODUCTION 83 5.13.2 KEY TARIFF RATES 84 5.13.3 PRICE IMPACT ANALYSIS 85 5.13.4 IMPACT ON COUNTRY/REGION 86 5.13.5 IMPACT ON END-USE SEGMENTS 87 5.13.5.1 Veterinary Hospitals 87 5.13.5.2 Veterinary Clinics 88 5.13.5.3 Other End Users (Veterinary Research Organizations, Government Vaccination Centers) 88 6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS 89 6.1 TECHNOLOGY ANALYSIS 89 6.1.1 KEY EMERGING TECHNOLOGIES 89 6.1.1.1 Recombinant DNA technology 89 6.1.1.2 mRNA-based vaccines 89 6.1.2 COMPLEMENTARY TECHNOLOGIES 90 6.1.2.1 Vaccine adjuvant technology 90 6.1.2.2 Needle-free & microneedle technology 90 6.1.3 ADJACENT TECHNOLOGIES 90 6.1.3.1 Genome editing technology 90 6.2 TECHNOLOGY/PRODUCT ROADMAP 91 6.2.1 NEAR TERM (2025–2027) 91 6.2.2 MID TERM (2028–2030) 91 6.2.3 LONG TERM (2030+) 92 6.3 PATENT ANALYSIS 92 6.3.1 JURISDICTION & TOP APPLICANT ANALYSIS 92 6.4 FUTURE APPLICATIONS 96 6.4.1 AI-ENABLED & DATA-DRIVEN PROCEDURE OPTIMIZATION 97 6.4.2 PERSONALIZED & PRECISION VACCINATION 97 6.4.3 CONNECTED ANIMAL HEALTH ECOSYSTEMS & DIGITAL INTEGRATION 97 6.5 IMPACT OF AI/GEN AI ON VETERINARY VACCINES MARKET 97 6.5.1 INTRODUCTION 97 6.5.2 MARKET POTENTIAL OF AI IN VETERINARY VACCINES 98 6.5.3 AI USE CASES 99 6.5.3.1 Vaccine Discovery and Antigen Identification 99 6.5.3.2 Disease Surveillance and Outbreak Prediction 99 6.5.3.3 Vaccine Formulation and Manufacturing Optimization 99 6.5.3.4 Precision Vaccination and Herd Health Management 99 6.5.3.5 Regulatory Intelligence and Scientific Workflow Automation 99 6.5.4 KEY COMPANIES IMPLEMENTING AI 100 7 SUSTAINABILITY & REGULATORY LANDSCAPE 102 7.1 REGIONAL REGULATIONS & COMPLIANCE 102 7.1.1 REGULATORY ANALYSIS 102 7.1.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 103 7.1.2.1 North America 103 7.1.2.2 Europe 104 7.1.2.3 Rest of the world 105 7.1.3 INDUSTRY STANDARDS 106 7.2 SUSTAINABILITY INITIATIVES 107 7.2.1 RECYCLED & ECO-FRIENDLY MATERIALS FOR VETERINARY VACCINES 107 7.2.2 SUSTAINABILITY IMPACT & REGULATORY POLICY INITIATIVES 107 7.2.3 CERTIFICATIONS, LABELING, AND ECO-STANDARDS 108 8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 109 8.1 KEY STAKEHOLDERS & BUYING CRITERIA 109 8.1.1 KEY STAKEHOLDERS IN BUYING PROCESS 109 8.1.2 BUYING CRITERIA 110 8.2 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 111 8.2.1 DECISION-MAKING PROCESS 111 8.2.2 ADOPTION BARRIERS & INTERNAL CHALLENGES 112 8.2.3 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES 113 8.2.4 MARKET PROFITABILITY 113 9 VETERINARY VACCINES MARKET, BY TYPE 115 9.1 INTRODUCTION 116 9.2 LIVESTOCK VACCINES 116 9.2.1 BOVINE VACCINES 118 9.2.1.1 Increasing demand for meat and milk to drive market 118 9.2.1.2 Global volume analysis of bovine vaccines, 2024–2031 (thousand units) 120 9.2.2 SMALL RUMINANT VACCINES 120 9.2.2.1 Increased livestock population and favorable government initiatives to propel market growth 120 9.2.2.2 Global volume analysis of small ruminant vaccines, 2024–2031 (thousand units) 123   9.3 PORCINE VACCINES 123 9.3.1 GROWING AWARENESS ABOUT ANIMAL VACCINATION TO SUPPORT MARKET GROWTH 123 9.3.1.1 Global volume analysis of porcine vaccines, 2024–2031 (thousand units) 126 9.4 POULTRY VACCINES 126 9.4.1 HIGH NEED FOR PROTEIN IN DAILY DIET TO AUGMENT MARKET GROWTH 126 9.4.1.1 Global volume analysis of poultry vaccines, 2024–2031 (thousand units) 129 9.5 COMPANION ANIMAL VACCINES 129 9.5.1 CANINE VACCINES 131 9.5.1.1 Increasing number of pet dogs and growing prevalence of zoonotic diseases to spur market growth 131 9.5.1.2 Global volume analysis of Canine vaccines, 2024–2031(thousand units) 133 9.5.2 FELINE VACCINES 133 9.5.2.1 Rising adoption of cats and growing need for better veterinary care to boost market growth 133 9.5.2.2 Global volume analysis of feline vaccines, 2024–2031 (thousand units) 135 9.6 AQUACULTURE VACCINES 135 9.6.1 INCREASED POPULARITY OF COMMERCIAL FISH FARMING TO FUEL MARKET GROWTH 135 9.6.1.1 Global volume analysis of aquaculture vaccines, 2024–2031 (thousand units) 137 9.7 OTHER VETERINARY VACCINES 137 10 VETERINARY VACCINES MARKET, BY DISEASE 139 10.1 INTRODUCTION 140 10.2 LIVESTOCK DISEASES 140 10.2.1 BOVINE DISEASES 142 10.2.1.1 Increasing government support to aid the market growth 142 10.2.2 SMALL RUMINANT DISEASES 143 10.2.2.1 Growing ruminant vaccines demand to propel the market growth 143 10.3 PORCINE DISEASES 144 10.3.1 PORCINE DISEASES TO ACCOUNT FOR LARGEST SHARE 144 10.4 POULTRY DISEASES 145 10.4.1 GROWING GOVERNMENT PROGRAMME TO CONTROL POULTRY DISEASES 145 10.5 COMPANION ANIMAL DISEASES 147 10.5.1 CANINE DISEASES 148 10.5.1.1 Innovative canine vaccine development to 148 10.5.2 FELINE DISEASES 149 10.5.2.1 Feline disease segment to grow at highest CAGR during forecast period 149   10.6 AQUACULTURE DISEASES 150 10.6.1 GROWING FOCUS ON DEVELOPING AQUACULTURE VACCINES 150 10.7 OTHER DISEASES 152 11 VETERINARY VACCINES MARKET, BY TECHNOLOGY 153 11.1 INTRODUCTION 154 11.2 LIVE ATTENUATED VACCINES 154 11.2.1 EASE OF ADMINISTRATION AND LONG-TERM IMMUNITY TO SUPPORT MARKET GROWTH 154 11.3 INACTIVATED VACCINES 155 11.3.1 NEED TO DEVELOP ARTIFICIAL IMMUNITY FROM NON-LIVING PATHOGENS TO DRIVE MARKET 155 11.4 TOXOID VACCINES 157 11.4.1 TOXOID VACCINES TO STIMULATE IMMUNE SYSTEM AND PROTECT ANIMALS FROM BACTERIAL TOXINS 157 11.5 RECOMBINANT VACCINES 158 11.5.1 BETTER STABILITY, HIGHER SAFETY, AND NO POST-VACCINATION REACTIONS TO SUPPORT VACCINE ADOPTION 158 11.6 OTHER VACCINE TECHNOLOGIES 159 12 VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION 160 12.1 INTRODUCTION 161 12.2 SUBCUTANEOUS ROUTE OF ADMINISTRATION 163 12.2.1 EASE OF ADMINISTRATION, REDUCED PAIN, AND LOWER RISK OF TISSUE DAMAGE TO AID MARKET GROWTH 163 12.3 INTRAMUSCULAR ROUTE OF ADMINISTRATION 165 12.3.1 BETTER IMMUNE RESPONSE AND LOWER RATE OF INJECTION-SITE REACTIONS TO AUGMENT MARKET GROWTH 165 12.4 ORAL ROUTE OF ADMINISTRATION 167 12.4.1 COST-EFFECTIVENESS, INCREASED SAFETY, AND HIGH PATIENT ACCEPTABILITY TO SUPPORT MARKET GROWTH 167 12.5 INTRANASAL/SPRAY ROUTE OF ADMINISTRATION 169 12.5.1 COST-EFFECTIVENESS AND RAPID ABSORPTION OF MEDICINE TO AID IN MASS VACCINATION 169 12.6 INTRAOCULAR ROUTE OF ADMINISTRATION 171 12.6.1 SIMPLE ADMINISTRATION OF VACCINES IN LARGE-SCALE FARMING OPERATIONS TO AID MARKET GROWTH 171 12.7 OTHER ROUTES OF ADMINISTRATION 173 13 VETERINARY VACCINES MARKET, BY END USER 175 13.1 INTRODUCTION 176 13.2 VETERINARY HOSPITALS 176 13.2.1 GROWING AWARENESS ABOUT ANIMAL HEALTH AND INCREASING VETERINARY EXPENDITURE BY PET OWNERS TO DRIVE MARKET 176   13.3 VETERINARY CLINICS 178 13.3.1 RISING NUMBER OF PET VISITS TO PRIVATE CLINICS TO SPUR MARKET GROWTH 178 13.4 OTHER END USERS 180 14 VETERINARY VACCINES MARKET, BY REGION 181 14.1 INTRODUCTION 182 14.2 NORTH AMERICA 182 14.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 183 14.2.2 NORTH AMERICA: VOLUME ANALYSIS OF VETERINARY VACCINES, BY TYPE, 2024–2031(THOUSAND UNITS) 184 14.2.3 US 188 14.2.3.1 US to dominate North American veterinary vaccines market during forecast period 188 14.2.4 CANADA 192 14.2.4.1 Rising pet ownership and increasing chicken consumption to drive demand for veterinary vaccines 192 14.3 EUROPE 196 14.3.1 EUROPE: VOLUME ANALYSIS OF VETERINARY VACCINES, BY TYPE, 2024–2031(THOUSAND UNITS) 197 14.3.2 MACROECONOMIC OUTLOOK FOR EUROPE 201 14.3.3 GERMANY 202 14.3.3.1 Increased poultry consumption and high pet healthcare expenditure to drive market 202 14.3.4 UK 206 14.3.4.1 Rising adoption of pets to augment market growth 206 14.3.5 FRANCE 210 14.3.5.1 Rising companion animal and livestock population to boost market growth 210 14.3.6 ITALY 214 14.3.6.1 Better availability of pet products through large-scale outlets to augment market growth 214 14.3.7 SPAIN 218 14.3.7.1 Increase in veterinary practices and willingness to spend on animal healthcare to drive market 218 14.3.8 NETHERLANDS 222 14.3.8.1 High-density livestock production and strong biosecurity standards to drive market growth 222 14.3.9 REST OF EUROPE 227 14.4 ASIA PACIFIC 232 14.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 232 14.4.2 ASIA PACIFIC: VOLUME ANALYSIS OF VETERINARY VACCINES, BY TYPE, 2024–2031(THOUSAND UNITS) 233 14.4.3 CHINA 238 14.4.3.1 Increasing companion animal population and growing incidence of zoonotic diseases to drive market 238 14.4.4 JAPAN 242 14.4.4.1 High consumption of animal-derived products and increased pet health expenditure to propel market growth 242 14.4.5 INDIA 246 14.4.5.1 Growth in poultry industry and high demand for dairy products to augment market growth 246 14.4.6 AUSTRALIA 250 14.4.6.1 Increase in per capita income and rise in meat consumption to aid market growth 250 14.4.7 SOUTH KOREA 254 14.4.7.1 High demand for animal protein and favorable government subsidies for meat production to spur market growth 254 14.4.8 REST OF ASIA PACIFIC 259 14.5 LATIN AMERICA 263 14.5.1 LATIN AMERICA: VOLUME ANALYSIS OF VETERINARY VACCINES, BY TYPE, 2024–2031(THOUSAND UNITS) 264 14.5.2 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 268 14.5.3 BRAZIL 269 14.5.3.1 Well-established livestock industry to promote market growth 269 14.5.4 MEXICO 273 14.5.4.1 Focus on pork and poultry meat production to fuel market growth 273 14.5.5 REST OF LATIN AMERICA 277 14.6 MIDDLE EAST & AFRICA 281 14.6.1 MIDDLE EAST & AFRICA: VOLUME ANALYSIS OF VETERINARY VACCINES, BY TYPE, 2024–2031(THOUSAND UNITS) 282 14.6.2 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 286 14.6.3 GCC COUNTRIES 287 14.6.3.1 Kingdom of Saudi Arabia 291 14.6.3.1.1 Favorable government initiatives for better animal health infrastructure to propel market growth 291 14.6.3.2 UAE 296 14.6.3.2.1 Favorable government initiatives to safeguard national livestock population and support sustainable agriculture 296 14.6.3.3 Rest of GCC countries 300 14.6.4 REST OF MIDDLE EAST & AFRICA 305 15 COMPETITIVE LANDSCAPE 310 15.1 INTRODUCTION 310 15.2 KEY PLAYER COMPETITIVE STRATEGIES/RIGHT TO WIN, 2024–2026 311 15.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN VETERINARY VACCINES MARKET 311 15.3 REVENUE ANALYSIS, 2023–2025 313 15.4 MARKET SHARE ANALYSIS, 2025 314 15.4.1 GLOBAL MARKET SHARE ANALYSIS (2025) 314   15.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025 316 15.5.1 STARS 316 15.5.2 EMERGING LEADERS 316 15.5.3 PERVASIVE PLAYERS 316 15.5.4 PARTICIPANTS 316 15.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025 318 15.5.5.1 Company footprint 318 15.5.5.2 Type footprint 319 15.5.5.3 Disease footprint 320 15.5.5.4 Technology footprint 321 15.5.5.5 Route of administration footprint 322 15.5.5.6 Region footprint 323 15.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 324 15.6.1 PROGRESSIVE COMPANIES 324 15.6.2 RESPONSIVE COMPANIES 324 15.6.3 DYNAMIC COMPANIES 324 15.6.4 STARTING BLOCKS 324 15.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025 326 15.6.5.1 Detailed list of key startups/SMEs 326 15.6.5.2 Competitive benchmarking of key startups/SMEs 327 15.7 COMPANY VALUATION & FINANCIAL METRICS 328 15.7.1 FINANCIAL METRICS 328 15.7.2 COMPANY VALUATION 328 15.8 BRAND/PRODUCT COMPARISON 329 15.9 COMPETITIVE SCENARIO 330 15.9.1 PRODUCT LAUNCHES & APPROVALS 330 15.9.2 DEALS 331 15.9.3 EXPANSIONS 331 15.9.4 OTHER DEVELOPMENTS 332 16 COMPANY PROFILES 333 16.1 KEY PLAYERS 333 16.1.1 MERCK & CO., INC. 333 16.1.1.1 Business overview 333 16.1.1.2 Products offered 335 16.1.1.3 Recent developments 338 16.1.1.3.1 Product launches & approvals 338 16.1.1.3.2 Deals 339 16.1.1.3.3 Expansions 339 16.1.1.4 MnM view 339 16.1.1.4.1 Right to win 339 16.1.1.4.2 Strategic choices 339 16.1.1.4.3 Weaknesses & competitive threats 339 16.1.2 ZOETIS SERVICES LLC 340 16.1.2.1 Business overview 340 16.1.2.2 Products offered 341 16.1.2.3 Recent developments 343 16.1.2.3.1 Product approvals 343 16.1.2.3.2 Deals 343 16.1.2.3.3 Expansions 343 16.1.2.3.4 Other developments 344 16.1.2.4 MnM view 344 16.1.2.4.1 Right to win 344 16.1.2.4.2 Strategic choices 344 16.1.2.4.3 Weaknesses & competitive threats 344 16.1.3 BOEHRINGER INGELHEIM INTERNATIONAL GMBH 345 16.1.3.1 Business overview 345 16.1.3.2 Products offered 346 16.1.3.3 Recent developments 347 16.1.3.3.1 Product launches 347 16.1.3.3.2 Expansions 348 16.1.3.4 MnM view 348 16.1.3.4.1 Right to win 348 16.1.3.4.2 Strategic choices 348 16.1.3.4.3 Weaknesses & competitive threats 348 16.1.4 ELANCO 349 16.1.4.1 Business overview 349 16.1.4.2 Products offered 350 16.1.4.3 Recent developments 352 16.1.4.3.1 Product approvals 352 16.1.4.3.2 Deals 352 16.1.4.4 MnM view 353 16.1.4.4.1 Right to win 353 16.1.4.4.2 Strategic choices 353 16.1.4.4.3 Weaknesses & competitive threats 353 16.1.5 VIRBAC 354 16.1.5.1 Business overview 354 16.1.5.2 Products offered 356 16.1.5.3 Recent developments 357 16.1.5.3.1 Product launches 357 16.1.5.3.2 Deals 358 16.1.5.3.3 Expansions 358 16.1.5.4 MnM view 359 16.1.5.4.1 Right to win 359 16.1.5.4.2 Strategic choices 359 16.1.5.4.3 Weaknesses & competitive threats 359 16.1.6 CEVA 360 16.1.6.1 Business overview 360 16.1.6.2 Products offered 360 16.1.6.3 Recent developments 362 16.1.6.3.1 Product launches 362 16.1.6.3.2 Expansions 362 16.1.7 PHIBRO ANIMAL HEALTH CORPORATION 363 16.1.7.1 Business overview 363 16.1.7.2 Products offered 364 16.1.8 HESTER BIOSCIENCES LIMITED 366 16.1.8.1 Business overview 366 16.1.8.2 Products offered 367 16.1.8.3 Recent developments 369 16.1.8.3.1 Product approvals 369 16.1.8.3.2 Deals 369 16.1.9 NEOGEN CORPORATION 370 16.1.9.1 Business overview 370 16.1.9.2 Products offered 371 16.1.9.3 Recent developments 372 16.1.9.3.1 Deals 372 16.1.10 HIPRA 373 16.1.10.1 Business overview 373 16.1.10.2 Products offered 373 16.1.10.3 Recent developments 375 16.1.10.3.1 Product launches 375 16.1.10.3.2 Deals 376 16.1.11 BIOGÉNESIS BAGÓ 377 16.1.11.1 Business overview 377 16.1.11.2 Products offered 377 16.1.11.3 Recent developments 378 16.1.11.3.1 Deals 378 16.1.11.3.2 Expansions 378 16.1.12 TIANJIN RINGPU BIO-TECHNOLOGY CO., LTD. 379 16.1.12.1 Business overview 379 16.1.12.2 Products offered 380 16.1.13 CHINA ANIMAL HUSBANDRY INDUSTRY CO., LTD. 382 16.1.13.1 Business overview 382 16.1.13.2 Products offered 382 16.1.13.2.1 Other developments 384   16.1.14 JINYU BIOTECHNOLOGY CO., LTD. 385 16.1.14.1 Business overview 385 16.1.14.2 Products offered 385 16.1.14.3 Recent developments 387 16.1.14.3.1 Product approvals 387 16.1.15 VAXXINOVA INTERNATIONAL B.V. 388 16.1.15.1 Business overview 388 16.1.15.2 Products offered 388 16.1.15.3 Recent developments 390 16.1.15.3.1 Product approvals 390 16.1.15.3.2 Deals 390 16.1.15.3.3 Expansions 391 16.2 OTHER COMPANIES 392 16.2.1 ENDOVAC ANIMAL HEALTH REBRAND CA 392 16.2.2 BRILLIANT BIO PHARMA PRIVATE LIMITED 393 16.2.3 APTIMMUNE 394 16.2.4 INDIAN IMMUNOLOGICALS LTD. 395 16.2.5 TORIGEN 396 16.2.6 INTAS PHARMACEUTICALS LTD. 396 16.2.7 OUROFINO S.A 397 16.2.8 BIOVAC LTD. 398 16.2.9 LABORATOIRE LCV 399 16.2.10 KYORITSU SEIYAKU CORPORATION 400 17 RESEARCH METHODOLOGY 401 17.1 RESEARCH DATA 401 17.1.1 SECONDARY DATA 401 17.1.1.1 Key data from secondary sources 403 17.1.2 PRIMARY DATA 404 17.1.2.1 Key data from primary sources 405 17.1.2.2 Key industry insights 405 17.1.2.3 Breakdown of primary interviews 406 17.1.2.4 Key industry insights 407 17.2 MARKET SIZE ESTIMATION 407 17.2.1 APPROACH 1: COMPANY REVENUE ANALYSIS APPROACH 408 17.2.2 APPROACH 2: CUSTOMER-BASED MARKET ESTIMATION 410 17.2.3 APPROACH 3: BOTTOM APPROACH 411 17.2.4 APPROACH 4: TOP-DOWN 411 17.2.5 BASE NUMBER CALCULATION 412 17.2.6 COMPANY PRESENTATIONS 412 17.2.7 PRIMARY INTERVIEWS 412 17.2.8 APPROACH 5: VOLUME ESTIMATION 412 17.2.9 APPROACH 6: DEMAND-SIDE 412 17.3 MARKET BREAKDOWN AND DATA TRIANGULATION 417 17.4 MARKET SHARE ASSESSMENT 418 17.5 RESEARCH ASSUMPTIONS 418 17.5.1 STUDY ASSUMPTIONS 418 17.5.2 GROWTH RATE ASSUMPTIONS 418 17.6 RISK ASSESSMENT 419 17.6.1 RESEARCH LIMITATIONS 419 18 APPENDIX 420 18.1 DISCUSSION GUIDE 420 18.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 426 18.3 CUSTOMIZATION OPTIONS 428 18.4 RELATED REPORTS 428 18.5 AUTHOR DETAILS 429

TABLE 1 STANDARD CURRENCY CONVERSION RATES 38 TABLE 2 GLOBAL MEAT MARKET INDICATORS, 2024 VS. 2025 52 TABLE 3 PAST AND PROJECTED TRENDS IN CONSUMPTION OF MEAT AND MILK (DEVELOPED VS. EMERGING MARKETS) 53 TABLE 4 ASIA: COUNTRY-LEVEL CONSUMPTION OF ANIMAL-DERIVED FOOD PRODUCTS, 2020 VS. 2030 (THOUSAND METRIC TONS) 53 TABLE 5 ASIA: COUNTRY-LEVEL PRODUCTION OF ANIMAL-DERIVED FOOD PRODUCTS, 2020 VS. 2030 (THOUSAND METRIC TONS) 54 TABLE 6 KEY COST AND OPERATIONAL CHALLENGES ASSOCIATED WITH VACCINE DEVELOPMENT 55 TABLE 7 VETERINARY VACCINES MARKET: PORTER’S FIVE FORCES ANALYSIS 63 TABLE 8 GDP CHANGE, BY KEY COUNTRY, 2021–2030 (USD BILLION) 66 TABLE 9 LIST OF KEY VETERINARY VACCINE MANUFACTURERS 71 TABLE 10 LIST OF KEY END USERS 72 TABLE 11 LIST OF KEY REGULATORY BODIES 73 TABLE 12 AVERAGE SELLING PRICE TREND OF VETERINARY VACCINES, BY KEY PLAYER, 2023–2025 (USD) 74 TABLE 13 AVERAGE SELLING PRICE TREND OF VETERINARY VACCINES, BY ROUTE OF ADMINISTRATION, 2023–2025 (USD) 75 TABLE 14 AVERAGE SELLING PRICE TREND OF VETERINARY VACCINES, BY END USER, 2023–2025 (USD) 76 TABLE 15 AVERAGE SELLING PRICE TREND OF CANINE VACCINES, BY REGION, 2023–2025 (USD) 77 TABLE 16 IMPORT DATA FOR HS CODE 3002-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2025 (USD THOUSAND) 78 TABLE 17 EXPORT DATA FOR HS CODE 3002-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2025 (USD THOUSAND) 78 TABLE 18 VETERINARY VACCINES MARKET: MAJOR CONFERENCES & EVENTS, 2026–2027 80 TABLE 19 BOVILIS NASALGEN-C: IMPROVED GROWTH PERFORMANCE AND REDUCED RESPIRATORY DISEASE IN VEAL CALVES 82 TABLE 20 UNISTRAIN PRRS: ENHANCED PRRS CONTROL AND REDUCED ANTIBIOTIC USAGE IN COMMERCIAL SWINE PRODUCTION 83 TABLE 21 FAO RABIES VACCINATION CASE STUDY 83 TABLE 22 RECIPROCAL TARIFF RATES ADJUSTED BY US, 2025 84 TABLE 23 KEY PRODUCT-RELATED TARIFF 85 TABLE 24 NORTH AMERICA: IMPACT OF US TARIFFS ON CANADA 86 TABLE 25 ASIA PACIFIC: IMPACT OF US TARIFFS ON CHINA, JAPAN, AND INDIA 86 TABLE 26 EUROPE: IMPACT OF US TARIFFS ON GERMANY AND UK 87 TABLE 27 LATIN AMERICA: IMPACT OF US TARIFFS ON MEXICO 87 TABLE 28 VETERINARY VACCINES MARKET: KEY PATENTS, 2023–2025 94 TABLE 29 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 103 TABLE 30 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 104 TABLE 31 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 105 TABLE 32 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF VETERINARY VACCINES 110 TABLE 33 KEY BUYING CRITERIA FOR VETERINARY VACCINES, BY END USER 111 TABLE 34 VETERINARY VACCINES MARKET: ADOPTION BARRIERS & INTERNAL CHALLENGES 112 TABLE 35 VETERINARY VACCINES MARKET: UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES 113 TABLE 36 VETERINARY VACCINES MARKET: KEY PROFITABILITY DRIVERS 114 TABLE 37 VETERINARY VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 116 TABLE 38 LIVESTOCK VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 116 TABLE 39 LIVESTOCK VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 117 TABLE 40 KEY PLAYERS PROVIDING BOVINE VACCINES 118 TABLE 41 BOVINE VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 119 TABLE 42 BOVINE VACCINES MARKET, BY REGION, 2024–2031 (THOUSAND UNITS) 120 TABLE 43 KEY PLAYERS PROVIDING SMALL RUMINANT VACCINES 121 TABLE 44 SMALL RUMINANT VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 122 TABLE 45 SMALL RUMINANT VACCINES MARKET, BY REGION, 2024–2031 (THOUSAND UNITS) 123 TABLE 46 KEY PLAYERS PROVIDING PORCINE VACCINES 124 TABLE 47 PORCINE VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 125 TABLE 48 PORCINE VACCINES MARKET, BY REGION, 2024–2031 (THOUSAND UNITS) 126 TABLE 49 KEY PLAYERS PROVIDING POULTRY VACCINES 127 TABLE 50 POULTRY VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 128 TABLE 51 POULTRY VACCINES MARKET, BY REGION, 2024–2031 (THOUSAND UNITS) 129 TABLE 52 COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 129 TABLE 53 COMPANION ANIMAL VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 130 TABLE 54 KEY PLAYERS PROVIDING CANINE VACCINES 131 TABLE 55 CANINE VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 132 TABLE 56 CANINE VACCINES MARKET, BY REGION, 2024–2031 (THOUSAND UNITS) 133 TABLE 57 KEY PLAYERS PROVIDING FELINE VACCINES 134 TABLE 58 FELINE VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 134 TABLE 59 FELINE VACCINES MARKET, BY REGION, 2024–2031 (THOUSAND UNITS) 135 TABLE 60 KEY PLAYERS PROVIDING AQUACULTURE VACCINES 136 TABLE 61 AQUACULTURE VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 136 TABLE 62 AQUACULTURE VACCINES MARKET, BY REGION, 2024–2031 (THOUSAND UNITS) 137 TABLE 63 KEY PLAYERS PROVIDING OTHER COMMERCIAL VETERINARY VACCINES 137 TABLE 64 OTHER VETERINARY VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 138 TABLE 65 VETERINARY VACCINES MARKET, BY DISEASE, 2024–2031 (USD MILLION) 140 TABLE 66 LIVESTOCK VACCINES MARKET, BY DISEASE, 2024–2031 (USD MILLION) 140 TABLE 67 LIVESTOCK DISEASES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 141 TABLE 68 BOVINE DISEASES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 142 TABLE 69 SMALL RUMINANT DISEASES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 143 TABLE 70 PORCINE DISEASES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 144 TABLE 71 POULTRY DISEASES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 146 TABLE 72 COMPANION ANIMAL VACCINES MARKET, BY DISEASE, 2024–2031 (USD MILLION) 147 TABLE 73 COMPANION ANIMAL DISEASES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 147 TABLE 74 CANINE DISEASES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 148 TABLE 75 FELINE DISEASES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 149 TABLE 76 AQUACULTURE DISEASES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 151 TABLE 77 OTHER DISEASES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 152 TABLE 78 VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 154 TABLE 79 LIVE ATTENUATED VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 155 TABLE 80 INACTIVATED VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 156 TABLE 81 TOXOID VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 157 TABLE 82 RECOMBINANT VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 158 TABLE 83 OTHER VACCINE TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 159 TABLE 84 ROUTES OF ADMINISTRATION FOR MAJOR VETERINARY VACCINES, BY KEY PLAYER 161 TABLE 85 VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 163 TABLE 86 COMMERCIALLY AVAILABLE VACCINES WITH SUBCUTANEOUS ROUTE OF ADMINISTRATION 163 TABLE 87 VETERINARY VACCINES MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2024–2031 (USD MILLION) 164 TABLE 88 COMMERCIALLY AVAILABLE VACCINES WITH INTRAMUSCULAR ROUTE OF ADMINISTRATION 165 TABLE 89 VETERINARY VACCINES MARKET FOR INTRAMUSCULAR ROUTE OF ADMINISTRATION, BY COUNTRY, 2024–2031 (USD MILLION) 166 TABLE 90 COMMERCIALLY AVAILABLE VACCINES WITH ORAL ROUTE OF ADMINISTRATION 167 TABLE 91 VETERINARY VACCINES MARKET FOR ORAL ROUTE OF ADMINISTRATION, BY COUNTRY, 2024–2031 (USD MILLION) 168 TABLE 92 COMMERCIALLY AVAILABLE VACCINES WITH INTRANASAL/SPRAY ROUTE OF ADMINISTRATION 169 TABLE 93 VETERINARY VACCINES MARKET FOR INTRANASAL/SPRAY ROUTE OF ADMINISTRATION, BY COUNTRY, 2024–2031 (USD MILLION) 170 TABLE 94 COMMERCIALLY AVAILABLE VACCINES WITH INTRAOCULAR ROUTE OF ADMINISTRATION 171 TABLE 95 VETERINARY VACCINES MARKET FOR INTRAOCULAR ROUTE OF ADMINISTRATION, BY COUNTRY, 2024–2031 (USD MILLION) 172 TABLE 96 COMMERCIALLY AVAILABLE VACCINES WITH OTHER ROUTES OF ADMINISTRATION 173 TABLE 97 VETERINARY VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2024–2031 (USD MILLION) 174 TABLE 98 VETERINARY VACCINES MARKET, BY END USER, 2024–2031 (USD MILLION) 176 TABLE 99 VETERINARY HOSPITALS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 177 TABLE 100 VETERINARY CLINICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 179 TABLE 101 OTHER END USERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 180 TABLE 102 VETERINARY VACCINES MARKET, BY REGION, 2024–2031 (USD MILLION) 182 TABLE 103 NORTH AMERICA: VETERINARY VACCINES MARKET, BY TYPE, 2024–2031(THOUSAND UNITS) 184 TABLE 104 NORTH AMERICA: VETERINARY VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 185 TABLE 105 NORTH AMERICA: VETERINARY VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 185 TABLE 106 NORTH AMERICA: LIVESTOCK VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 185 TABLE 107 NORTH AMERICA: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 186 TABLE 108 NORTH AMERICA: VETERINARY VACCINES MARKET, BY DISEASE, 2024–2031 (USD MILLION) 186 TABLE 109 NORTH AMERICA: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2024–2031 (USD MILLION) 187 TABLE 110 NORTH AMERICA: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2024–2031 (USD MILLION) 187 TABLE 111 NORTH AMERICA: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 187 TABLE 112 NORTH AMERICA: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 188 TABLE 113 NORTH AMERICA: VETERINARY VACCINES MARKET, BY END USER, 2024–2031 (USD MILLION) 188 TABLE 114 US: KEY MACROINDICATORS 189 TABLE 115 US: VETERINARY VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 189 TABLE 116 US: LIVESTOCK VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 190 TABLE 117 US: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 190 TABLE 118 US: VETERINARY VACCINES MARKET, BY DISEASE, 2024–2031 (USD MILLION) 190 TABLE 119 US: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2024–2031 (USD MILLION) 191 TABLE 120 US: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2024–2031 (USD MILLION) 191 TABLE 121 US: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 191 TABLE 122 US: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 192 TABLE 123 US: VETERINARY VACCINES MARKET, BY END USER, 2024–2031 (USD MILLION) 192 TABLE 124 CANADA: KEY MACROINDICATORS 193 TABLE 125 CANADA: VETERINARY VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 193 TABLE 126 CANADA: LIVESTOCK VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 194 TABLE 127 CANADA: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 194 TABLE 128 CANADA: VETERINARY VACCINES MARKET, BY DISEASE, 2024–2031 (USD MILLION) 194 TABLE 129 CANADA: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2024–2031 (USD MILLION) 195 TABLE 130 CANADA: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2024–2031 (USD MILLION) 195 TABLE 131 CANADA: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 195 TABLE 132 CANADA: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 196 TABLE 133 CANADA: VETERINARY VACCINES MARKET, BY END USER, 2024–2031 (USD MILLION) 196 TABLE 134 EUROPE: VETERINARY VACCINES MARKET, BY TYPE, 2024–2031(THOUSAND UNITS) 197 TABLE 135 EUROPE: VETERINARY VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 198 TABLE 136 EUROPE: VETERINARY VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 198 TABLE 137 EUROPE: LIVESTOCK VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 199 TABLE 138 EUROPE: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 199 TABLE 139 EUROPE: VETERINARY VACCINES MARKET, BY DISEASE, 2024–2031 (USD MILLION) 199 TABLE 140 EUROPE: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2024–2031 (USD MILLION) 200 TABLE 141 EUROPE: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2024–2031 (USD MILLION) 200 TABLE 142 EUROPE: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 200 TABLE 143 EUROPE: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 201 TABLE 144 EUROPE: VETERINARY VACCINES MARKET, BY END USER, 2024–2031 (USD MILLION) 201 TABLE 145 GERMANY: KEY MACROINDICATORS 202 TABLE 146 GERMANY: VETERINARY VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 203 TABLE 147 GERMANY: LIVESTOCK VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 203 TABLE 148 GERMANY: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 204 TABLE 149 GERMANY: VETERINARY VACCINES MARKET, BY DISEASE, 2024–2031 (USD MILLION) 204 TABLE 150 GERMANY: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2024–2031 (USD MILLION) 205 TABLE 151 GERMANY: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2024–2031 (USD MILLION) 205 TABLE 152 GERMANY: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 205 TABLE 153 GERMANY: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 206 TABLE 154 GERMANY: VETERINARY VACCINES MARKET, BY END USER, 2024–2031 (USD MILLION) 206 TABLE 155 UK: KEY MACROINDICATORS 207 TABLE 156 UK: VETERINARY VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 207 TABLE 157 UK: LIVESTOCK VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 207 TABLE 158 UK: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 208 TABLE 159 UK: VETERINARY VACCINES MARKET, BY DISEASE, 2024–2031 (USD MILLION) 208 TABLE 160 UK: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2024–2031 (USD MILLION) 208 TABLE 161 UK: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2024–2031 (USD MILLION) 209 TABLE 162 UK: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 209 TABLE 163 UK: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 210 TABLE 164 UK: VETERINARY VACCINES MARKET, BY END USER, 2024–2031 (USD MILLION) 210 TABLE 165 FRANCE: KEY MACROINDICATORS 211 TABLE 166 FRANCE: VETERINARY VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 211 TABLE 167 FRANCE: LIVESTOCK VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 212 TABLE 168 FRANCE: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 212 TABLE 169 FRANCE: VETERINARY VACCINES MARKET, BY DISEASE, 2024–2031 (USD MILLION) 212 TABLE 170 FRANCE: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2024–2031 (USD MILLION) 213 TABLE 171 FRANCE: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2024–2031 (USD MILLION) 213 TABLE 172 FRANCE: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 213 TABLE 173 FRANCE: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 214 TABLE 174 FRANCE: VETERINARY VACCINES MARKET, BY END USER, 2024–2031 (USD MILLION) 214 TABLE 175 ITALY: KEY MACROINDICATORS 215 TABLE 176 ITALY: VETERINARY VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 215 TABLE 177 ITALY: LIVESTOCK VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 215 TABLE 178 ITALY: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 216 TABLE 179 ITALY: VETERINARY VACCINES MARKET, BY DISEASE, 2024–2031 (USD MILLION) 216 TABLE 180 ITALY: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2024–2031 (USD MILLION) 217 TABLE 181 ITALY: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2024–2031 (USD MILLION) 217 TABLE 182 ITALY: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 217 TABLE 183 ITALY: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 218 TABLE 184 ITALY: VETERINARY VACCINES MARKET, BY END USER, 2024–2031 (USD MILLION) 218 TABLE 185 SPAIN: KEY MACROINDICATORS 219 TABLE 186 SPAIN: VETERINARY VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 219 TABLE 187 SPAIN: LIVESTOCK VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 220 TABLE 188 SPAIN: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 220 TABLE 189 SPAIN: VETERINARY VACCINES MARKET, BY DISEASE, 2024–2031 (USD MILLION) 220 TABLE 190 SPAIN: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2024–2031 (USD MILLION) 221 TABLE 191 SPAIN: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2024–2031 (USD MILLION) 221 TABLE 192 SPAIN: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 221 TABLE 193 SPAIN: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 222 TABLE 194 SPAIN: VETERINARY VACCINES MARKET, BY END USER, 2024–2031 (USD MILLION) 222 TABLE 195 NETHERLANDS: KEY MACROINDICATORS 223 TABLE 196 NETHERLANDS: VETERINARY VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 223 TABLE 197 NETHERLANDS: LIVESTOCK VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 224 TABLE 198 NETHERLANDS: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 224 TABLE 199 NETHERLANDS: VETERINARY VACCINES MARKET, BY DISEASE, 2024–2031 (USD MILLION) 224 TABLE 200 NETHERLANDS: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2024–2031 (USD MILLION) 225 TABLE 201 NETHERLANDS: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2024–2031 (USD MILLION) 225 TABLE 202 NETHERLANDS: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 226 TABLE 203 NETHERLANDS: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 226 TABLE 204 NETHERLANDS: VETERINARY VACCINES MARKET, BY END USER, 2024–2031 (USD MILLION) 227 TABLE 205 REST OF EUROPE: VETERINARY VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 228 TABLE 206 REST OF EUROPE: LIVESTOCK VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 228 TABLE 207 REST OF EUROPE: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 228 TABLE 208 REST OF EUROPE: VETERINARY VACCINES MARKET, BY DISEASE, 2024–2031 (USD MILLION) 229 TABLE 209 REST OF EUROPE: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2024–2031 (USD MILLION) 229 TABLE 210 REST OF EUROPE: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2024–2031 (USD MILLION) 230 TABLE 211 REST OF EUROPE: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 230 TABLE 212 REST OF EUROPE: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 231 TABLE 213 REST OF EUROPE: VETERINARY VACCINES MARKET, BY END USER, 2024–2031 (USD MILLION) 231 TABLE 214 ASIA PACIFIC: VETERINARY VACCINES MARKET, BY TYPE, 2024–2031(THOUSAND UNITS) 233 TABLE 215 ASIA PACIFIC: VETERINARY VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 234 TABLE 216 ASIA PACIFIC: VETERINARY VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 234 TABLE 217 ASIA PACIFIC: LIVESTOCK VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 235 TABLE 218 ASIA PACIFIC: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 235 TABLE 219 ASIA PACIFIC: VETERINARY VACCINES MARKET, BY DISEASE, 2024–2031 (USD MILLION) 235 TABLE 220 ASIA PACIFIC: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2024–2031 (USD MILLION) 236 TABLE 221 ASIA PACIFIC: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2024–2031 (USD MILLION) 236 TABLE 222 ASIA PACIFIC: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 237 TABLE 223 ASIA PACIFIC: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 237 TABLE 224 ASIA PACIFIC: VETERINARY VACCINES MARKET, BY END USER, 2024–2031 (USD MILLION) 238 TABLE 225 CHINA: KEY MACROINDICATORS 238 TABLE 226 CHINA: VETERINARY VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 239 TABLE 227 CHINA: LIVESTOCK VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 239 TABLE 228 CHINA: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 239 TABLE 229 CHINA: VETERINARY VACCINES MARKET, BY DISEASE, 2024–2031 (USD MILLION) 240 TABLE 230 CHINA: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2024–2031 (USD MILLION) 240 TABLE 231 CHINA: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2024–2031 (USD MILLION) 241 TABLE 232 CHINA: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 241 TABLE 233 CHINA: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 242 TABLE 234 CHINA: VETERINARY VACCINES MARKET, BY END USER, 2024–2031 (USD MILLION) 242 TABLE 235 JAPAN: KEY MACROINDICATORS 243 TABLE 236 JAPAN: VETERINARY VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 243 TABLE 237 JAPAN: LIVESTOCK VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 244 TABLE 238 JAPAN: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 244 TABLE 239 JAPAN: VETERINARY VACCINES MARKET, BY DISEASE, 2024–2031 (USD MILLION) 244 TABLE 240 JAPAN: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2024–2031 (USD MILLION) 245 TABLE 241 JAPAN: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2024–2031 (USD MILLION) 245 TABLE 242 JAPAN: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 245 TABLE 243 JAPAN: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 246 TABLE 244 JAPAN: VETERINARY VACCINES MARKET, BY END USER, 2024–2031 (USD MILLION) 246 TABLE 245 INDIA: KEY MACROINDICATORS 247 TABLE 246 INDIA: VETERINARY VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 247 TABLE 247 INDIA: LIVESTOCK VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 248 TABLE 248 INDIA: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 248 TABLE 249 INDIA: VETERINARY VACCINES MARKET, BY DISEASE, 2024–2031 (USD MILLION) 248 TABLE 250 INDIA: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2024–2031 (USD MILLION) 249 TABLE 251 INDIA: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2024–2031 (USD MILLION) 249 TABLE 252 INDIA: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 249 TABLE 253 INDIA: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 250 TABLE 254 INDIA: VETERINARY VACCINES MARKET, BY END USER, 2024–2031 (USD MILLION) 250 TABLE 255 AUSTRALIA: KEY MACROINDICATORS 251 TABLE 256 AUSTRALIA: VETERINARY VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 251 TABLE 257 AUSTRALIA: LIVESTOCK VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 252 TABLE 258 AUSTRALIA: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 252 TABLE 259 AUSTRALIA: VETERINARY VACCINES MARKET, BY DISEASE, 2024–2031 (USD MILLION) 252 TABLE 260 AUSTRALIA: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2024–2031 (USD MILLION) 253 TABLE 261 AUSTRALIA: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2024–2031 (USD MILLION) 253 TABLE 262 AUSTRALIA: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 253 TABLE 263 AUSTRALIA: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 254 TABLE 264 AUSTRALIA: VETERINARY VACCINES MARKET, BY END USER, 2024–2031 (USD MILLION) 254 TABLE 265 SOUTH KOREA: KEY MACROINDICATORS 255 TABLE 266 SOUTH KOREA: VETERINARY VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 255 TABLE 267 SOUTH KOREA: LIVESTOCK VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 256 TABLE 268 SOUTH KOREA: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 256 TABLE 269 SOUTH KOREA: VETERINARY VACCINES MARKET, BY DISEASE, 2024–2031 (USD MILLION) 257 TABLE 270 SOUTH KOREA: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2024–2031 (USD MILLION) 257 TABLE 271 SOUTH KOREA: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2024–2031 (USD MILLION) 258 TABLE 272 SOUTH KOREA: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 258 TABLE 273 SOUTH KOREA: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 259 TABLE 274 SOUTH KOREA: VETERINARY VACCINES MARKET, BY END USER, 2024–2031 (USD MILLION) 259 TABLE 275 REST OF ASIA PACIFIC: VETERINARY VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 260 TABLE 276 REST OF ASIA PACIFIC: LIVESTOCK VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 260 TABLE 277 REST OF ASIA PACIFIC: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 261 TABLE 278 REST OF ASIA PACIFIC: VETERINARY VACCINES MARKET, BY DISEASE, 2024–2031 (USD MILLION) 261 TABLE 279 REST OF ASIA PACIFIC: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2024–2031 (USD MILLION) 262 TABLE 280 REST OF ASIA PACIFIC: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2024–2031 (USD MILLION) 262 TABLE 281 REST OF ASIA PACIFIC: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 262 TABLE 282 REST OF ASIA PACIFIC: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 263 TABLE 283 REST OF ASIA PACIFIC: VETERINARY VACCINES MARKET, BY END USER, 2024–2031 (USD MILLION) 263 TABLE 284 LATIN AMERICA: VETERINARY VACCINES MARKET, BY TYPE, 2024–2031(THOUSAND UNITS) 264 TABLE 285 LATIN AMERICA: VETERINARY VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 264 TABLE 286 LATIN AMERICA: VETERINARY VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 265 TABLE 287 LATIN AMERICA: LIVESTOCK VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 265 TABLE 288 LATIN AMERICA: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 265 TABLE 289 LATIN AMERICA: VETERINARY VACCINES MARKET, BY DISEASE, 2024–2031 (USD MILLION) 266 TABLE 290 LATIN AMERICA: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2024–2031 (USD MILLION) 266 TABLE 291 LATIN AMERICA: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2024–2031 (USD MILLION) 267 TABLE 292 LATIN AMERICA: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 267 TABLE 293 LATIN AMERICA: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 268 TABLE 294 LATIN AMERICA: VETERINARY VACCINES MARKET, BY END USER, 2024–2031 (USD MILLION) 268 TABLE 295 BRAZIL: KEY MACROINDICATORS 269 TABLE 296 BRAZIL: VETERINARY VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 270 TABLE 297 BRAZIL: LIVESTOCK VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 270 TABLE 298 BRAZIL: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 270 TABLE 299 BRAZIL: VETERINARY VACCINES MARKET, BY DISEASE, 2024–2031 (USD MILLION) 271 TABLE 300 BRAZIL: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2024–2031 (USD MILLION) 271 TABLE 301 BRAZIL: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2024–2031 (USD MILLION) 272 TABLE 302 BRAZIL: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 272 TABLE 303 BRAZIL: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 273 TABLE 304 BRAZIL: VETERINARY VACCINES MARKET, BY END USER, 2024–2031 (USD MILLION) 273 TABLE 305 MEXICO: KEY MACROINDICATORS 274 TABLE 306 MEXICO: VETERINARY VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 274 TABLE 307 MEXICO: LIVESTOCK VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 275 TABLE 308 MEXICO: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 275 TABLE 309 MEXICO: VETERINARY VACCINES MARKET, BY DISEASE, 2024–2031 (USD MILLION) 275 TABLE 310 MEXICO: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2024–2031 (USD MILLION) 276 TABLE 311 MEXICO: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2024–2031 (USD MILLION) 276 TABLE 312 MEXICO: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 276 TABLE 313 MEXICO: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 277 TABLE 314 MEXICO: VETERINARY VACCINES MARKET, BY END USER, 2024–2031 (USD MILLION) 277 TABLE 315 REST OF LATIN AMERICA: VETERINARY VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 278 TABLE 316 REST OF LATIN AMERICA: LIVESTOCK VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 278 TABLE 317 REST OF LATIN AMERICA: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 279 TABLE 318 REST OF LATIN AMERICA: VETERINARY VACCINES MARKET, BY DISEASE, 2024–2031 (USD MILLION) 279 TABLE 319 REST OF LATIN AMERICA: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2024–2031 (USD MILLION) 280 TABLE 320 REST OF LATIN AMERICA: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2024–2031 (USD MILLION) 280 TABLE 321 REST OF LATIN AMERICA: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 280 TABLE 322 REST OF LATIN AMERICA: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 281 TABLE 323 REST OF LATIN AMERICA: VETERINARY VACCINES MARKET, BY END USER, 2024–2031 (USD MILLION) 281 TABLE 324 MIDDLE EAST & AFRICA: VETERINARY VACCINES MARKET, BY TYPE, 2024–2031(THOUSAND UNITS) 282 TABLE 325 MIDDLE EAST & AFRICA: VETERINARY VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 282 TABLE 326 MIDDLE EAST & AFRICA: VETERINARY VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 283 TABLE 327 MIDDLE EAST & AFRICA: LIVESTOCK VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 283 TABLE 328 MIDDLE EAST & AFRICA: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 284 TABLE 329 MIDDLE EAST & AFRICA: VETERINARY VACCINES MARKET, BY DISEASE, 2024–2031 (USD MILLION) 284 TABLE 330 MIDDLE EAST & AFRICA: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2024–2031 (USD MILLION) 285 TABLE 331 MIDDLE EAST & AFRICA: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2024–2031 (USD MILLION) 285 TABLE 332 MIDDLE EAST & AFRICA: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 285 TABLE 333 MIDDLE EAST & AFRICA: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 286 TABLE 334 MIDDLE EAST & AFRICA: VETERINARY VACCINES MARKET, BY END USER, 2024–2031 (USD MILLION) 286 TABLE 335 GCC COUNTRIES: VETERINARY VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 287 TABLE 336 GCC COUNTRIES: LIVESTOCK VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 288 TABLE 337 GCC COUNTRIES: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 288 TABLE 338 GCC COUNTRIES: VETERINARY VACCINES MARKET, BY DISEASE, 2024–2031 (USD MILLION) 289 TABLE 339 GCC COUNTRIES: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2024–2031 (USD MILLION) 289 TABLE 340 GCC COUNTRIES: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2024–2031 (USD MILLION) 290 TABLE 341 GCC COUNTRIES: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 290 TABLE 342 GCC COUNTRIES: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 291 TABLE 343 GCC COUNTRIES: VETERINARY VACCINES MARKET, BY END USER, 2024–2031 (USD MILLION) 291 TABLE 344 KINGDOM OF SAUDI ARABIA: KEY MACROINDICATORS 292 TABLE 345 KINGDOM OF SAUDI ARABIA: VETERINARY VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 292 TABLE 346 KINGDOM OF SAUDI ARABIA: LIVESTOCK VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 293 TABLE 347 KINGDOM OF SAUDI ARABIA: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 293 TABLE 348 KINGDOM OF SAUDI ARABIA: VETERINARY VACCINES MARKET, BY DISEASE, 2024–2031 (USD MILLION) 294 TABLE 349 KINGDOM OF SAUDI ARABIA: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2024–2031 (USD MILLION) 294 TABLE 350 KINGDOM OF SAUDI ARABIA: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2024–2031 (USD MILLION) 295 TABLE 351 KINGDOM OF SAUDI ARABIA: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 295 TABLE 352 KINGDOM OF SAUDI ARABIA: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 296 TABLE 353 KINGDOM OF SAUDI ARABIA: VETERINARY VACCINES MARKET, BY END USER, 2024–2031 (USD MILLION) 296 TABLE 354 UNITED ARAB EMIRATES: KEY MACROINDICATORS 297 TABLE 355 UAE: VETERINARY VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 297 TABLE 356 UAE: LIVESTOCK VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 298 TABLE 357 UAE: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 298 TABLE 358 UAE: VETERINARY VACCINES MARKET, BY DISEASE, 2024–2031 (USD MILLION) 298 TABLE 359 UAE: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2024–2031 (USD MILLION) 299 TABLE 360 UAE: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2024–2031 (USD MILLION) 299 TABLE 361 UAE: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 299 TABLE 362 UAE: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 300 TABLE 363 UAE: VETERINARY VACCINES MARKET, BY END USER, 2024–2031 (USD MILLION) 300 TABLE 364 REST OF GCC COUNTRIES: VETERINARY VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 301 TABLE 365 REST OF GCC COUNTRIES: LIVESTOCK VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 301 TABLE 366 REST OF GCC COUNTRIES: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 302 TABLE 367 REST OF GCC COUNTRIES: VETERINARY VACCINES MARKET, BY DISEASE, 2024–2031 (USD MILLION) 302 TABLE 368 REST OF GCC COUNTRIES: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2024–2031 (USD MILLION) 303 TABLE 369 REST OF GCC COUNTRIES: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2024–2031 (USD MILLION) 303 TABLE 370 REST OF GCC COUNTRIES: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 304 TABLE 371 REST OF GCC COUNTRIES: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 304 TABLE 372 REST OF GCC COUNTRIES: VETERINARY VACCINES MARKET, BY END USER, 2024–2031 (USD MILLION) 305 TABLE 373 REST OF MIDDLE EAST & AFRICA: VETERINARY VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 305 TABLE 374 REST OF MIDDLE EAST & AFRICA: LIVESTOCK VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 306 TABLE 375 REST OF MIDDLE EAST & AFRICA: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 306 TABLE 376 REST OF MIDDLE EAST & AFRICA: VETERINARY VACCINES MARKET, BY DISEASE, 2024–2031 (USD MILLION) 307 TABLE 377 REST OF MIDDLE EAST & AFRICA: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2024–2031 (USD MILLION) 307 TABLE 378 REST OF MIDDLE EAST & AFRICA: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2024–2031 (USD MILLION) 308 TABLE 379 REST OF MIDDLE EAST & AFRICA VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 308 TABLE 380 REST OF MIDDLE EAST & AFRICA: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 309 TABLE 381 REST OF MIDDLE EAST & AFRICA: VETERINARY VACCINES MARKET, BY END USER, 2024–2031 (USD MILLION) 309 TABLE 382 OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN VETERINARY VACCINES MARKET, JANUARY 2023–MAY 2026 311 TABLE 383 VETERINARY VACCINES MARKET: DEGREE OF COMPETITION 315 TABLE 384 VETERINARY VACCINES MARKET: TYPE FOOTPRINT 319 TABLE 385 VETERINARY VACCINES MARKET: DISEASE FOOTPRINT 320 TABLE 386 VETERINARY VACCINES MARKET: TECHNOLOGY FOOTPRINT 321 TABLE 387 VETERINARY VACCINES MARKET: ROUTE OF ADMINISTRATION FOOTPRINT 322 TABLE 388 VETERINARY VACCINES MARKET: REGION FOOTPRINT 323 TABLE 389 VETERINARY VACCINES MARKET: DETAILED LIST OF KEY STARTUPS/SMES 326 TABLE 390 VETERINARY VACCINES MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUP/SME PLAYERS 327 TABLE 391 VETERINARY VACCINES MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–MAY 2026 330 TABLE 392 VETERINARY VACCINES MARKET: DEALS, JANUARY 2023–MAY 2026 331 TABLE 393 VETERINARY VACCINES MARKET: EXPANSIONS, JANUARY 2023–MAY 2026 331 TABLE 394 VETERINARY VACCINES MARKET: OTHER DEVELOPMENTS, JANUARY 2023–MAY 2026 332 TABLE 395 MERCK & CO., INC.: COMPANY OVERVIEW 333 TABLE 396 MERCK & CO., INC.: PRODUCTS OFFERED 335 TABLE 397 MERCK & CO., INC.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023—MAY 2026 338 TABLE 398 MERCK & CO., INC.: DEALS, JANUARY 2023—MAY 2026 339 TABLE 399 MERCK & CO., INC.: EXPANSIONS, JANUARY 2023—MAY 2026 339 TABLE 400 ZOETIS SERVICES LLC: COMPANY OVERVIEW 340 TABLE 401 ZOETIS SERVICES LLC: PRODUCTS OFFERED 341 TABLE 402 ZOETIS SERVICES LLC: PRODUCT APPROVALS, JANUARY 2023—MAY 2026 343 TABLE 403 ZOETIS SERVICES LLC: DEALS, JANUARY 2023—MAY 2026 343 TABLE 404 ZOETIS SERVICES LLC: EXPANSIONS, JANUARY 2023−MAY 2026 343 TABLE 405 ZOETIS SERVICES LLC: OTHER DEVELOPMENTS, JANUARY 2023−MAY 2026 344 TABLE 406 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY OVERVIEW 345 TABLE 407 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: PRODUCTS OFFERED 346 TABLE 408 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: PRODUCT LAUNCHES, JANUARY 2023—MAY 2026 347 TABLE 409 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: EXPANSIONS, JANUARY 2023−MAY 2026 348 TABLE 410 ELANCO: COMPANY OVERVIEW 349 TABLE 411 ELANCO: PRODUCTS OFFERED 350 TABLE 412 ELANCO: PRODUCT APPROVALS JANUARY 2023—MAY 2026 352 TABLE 413 ELANCO: DEALS, JANUARY 2023–MAY 2026 352 TABLE 414 VIRBAC: COMPANY OVERVIEW 354 TABLE 415 VIRBAC: PRODUCTS OFFERED 356 TABLE 416 VIRBAC: PRODUCT LAUNCHES, JANUARY 2023—MAY 2026 357 TABLE 417 VIRBAC: DEALS, JANUARY 2023–MAY 2026 358 TABLE 418 VIRBAC: EXPANSIONS, JANUARY 2023–MAY 2026 358 TABLE 419 CEVA: COMPANY OVERVIEW 360 TABLE 420 CEVA: PRODUCTS OFFERED 360 TABLE 421 CEVA: PRODUCT LAUNCHES: JANUARY 2023—MAY 2026 362 TABLE 422 CEVA: EXPANSIONS, JANUARY 2023–MAY 2026 362 TABLE 423 PHIBRO ANIMAL HEALTH CORPORATION: COMPANY OVERVIEW 363 TABLE 424 PHIBRO ANIMAL HEALTH CORPORATION: PRODUCTS OFFERED 364 TABLE 425 HESTER BIOSCIENCES LIMITED: COMPANY OVERVIEW 366 TABLE 426 HESTER BIOSCIENCES LIMITED: PRODUCTS OFFERED 367 TABLE 427 HESTER BIOSCIENCES LIMITED: PRODUCT APPROVALS, JANUARY 2023—MAY 2026 369 TABLE 428 HESTER BIOSCIENCES LIMITED: DEALS, JANUARY 2023–MAY 2026 369 TABLE 429 NEOGEN CORPORATION: COMPANY OVERVIEW 370 TABLE 430 NEOGEN CORPORATION: PRODUCTS OFFERED 371 TABLE 431 NEOGEN CORPORATION: DEALS, JANUARY 2023–MAY 2026 372 TABLE 432 HIPRA: COMPANY OVERVIEW 373 TABLE 433 HIPRA: PRODUCTS OFFERED 373 TABLE 434 HIPRA: PRODUCT LAUNCHES, JANUARY 2023—MAY 2026 375 TABLE 435 HIPRA: DEALS, JANUARY 2023–MAY 2026 376 TABLE 436 BIOGÉNESIS BAGÓ: COMPANY OVERVIEW 377 TABLE 437 BIOGÉNESIS BAGÓ: PRODUCTS OFFERED 377 TABLE 438 BIOGÉNESIS BAGÓ: DEALS, JANUARY 2023–MAY 2026 378 TABLE 439 BIOGÉNESIS BAGÓ: EXPANSIONS, JANUARY 2023–MAY 2026 378 TABLE 440 TIANJIN RINGPU BIO-TECHNOLOGY CO., LTD.: COMPANY OVERVIEW 379 TABLE 441 TIANJIN RINGPU BIO-TECHNOLOGY CO., LTD.: PRODUCTS OFFERED 380 TABLE 442 CHINA ANIMAL HUSBANDRY INDUSTRY CO., LTD.: COMPANY OVERVIEW 382 TABLE 443 CHINA ANIMAL HUSBANDRY INDUSTRY CO., LTD.: PRODUCTS OFFERED 382 TABLE 444 CHINA ANIMAL HUSBANDRY INDUSTRY CO., LTD.: OTHER DEVELOPMENTS, JANUARY 2023–MAY 2026 384 TABLE 445 JINYU BIOTECHNOLOGY CO., LTD.: COMPANY OVERVIEW 385 TABLE 446 JINYU BIOTECHNOLOGY CO., LTD.: PRODUCTS OFFERED 385 TABLE 447 JINYU BIOTECHNOLOGY CO., LTD.: PRODUCT APPROVALS, JANUARY 2023–MAY 2026 387 TABLE 448 VAXXINOVA INTERNATIONAL B.V.: COMPANY OVERVIEW 388 TABLE 449 VAXXINOVA INTERNATIONAL B.V.: PRODUCTS OFFERED 388 TABLE 450 VAXXINOVA INTERNATIONAL B.V.: PRODUCT APPROVALS, JANUARY 2023–MAY 2026 390 TABLE 451 VAXXINOVA INTERNATIONAL B.V.: DEALS, JANUARY 2023–MAY 2026 390 TABLE 452 VAXXINOVA INTERNATIONAL B.V.: EXPANSIONS, JANUARY 2023–MAY 2026 391 TABLE 453 ENDOVAC ANIMAL HEALTH REBRAND CA: COMPANY OVERVIEW 392 TABLE 454 BRILLIANT BIO PHARMA PRIVATE LIMITED: COMPANY OVERVIEW 393 TABLE 455 APTIMMUNE: COMPANY OVERVIEW 394 TABLE 456 INDIAN IMMUNOLOGICALS LTD.: COMPANY OVERVIEW 395 TABLE 457 TORIGEN: COMPANY OVERVIEW 396 TABLE 458 INTAS PHARMACEUTICALS LTD.: COMPANY OVERVIEW 396 TABLE 459 OUROFINO S.A: COMPANY OVERVIEW 397 TABLE 460 BIOVAC LTD.: COMPANY OVERVIEW 398 TABLE 461 LABORATOIRE LCV.: COMPANY OVERVIEW 399 TABLE 462 KYORITSU SEIYAKU CORPORATION.: COMPANY OVERVIEW 400 TABLE 463 STUDY ASSUMPTIONS 418 TABLE 464 VETERINARY VACCINES MARKET: RISK ASSESSMENT ANALYSIS 419 FIGURE 1 VETERINARY VACCINES MARKET SEGMENTATION & REGIONAL SCOPE 36 FIGURE 2 MARKET SCENARIO 40 FIGURE 3 GLOBAL VETERINARY VACCINES MARKET, 2024–2031 41 FIGURE 4 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS VETERINARY VACCINES MARKET, 2024–2026 41 FIGURE 5 DISRUPTIONS INFLUENCING GROWTH OF VETERINARY VACCINES MARKET 42 FIGURE 6 HIGH-GROWTH SEGMENTS IN VETERINARY VACCINES MARKET, 2026–2031 43 FIGURE 7 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN VETERINARY VACCINES MARKET, IN TERMS OF VALUE, DURING FORECAST PERIOD 44 FIGURE 8 RISING COMPANION ANIMAL OWNERSHIP TO DRIVE MARKET GROWTH 45 FIGURE 9 VETERINARY HOSPITALS SEGMENT IN ASIA PACIFIC REGION ACCOUNTED FOR LARGEST SHARE IN 2025 46 FIGURE 10 INDIA TO WITNESS HIGHEST CAGR DURING FORECAST PERIOD 47 FIGURE 11 VETERINARY VACCINES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 48 FIGURE 12 US: PET OWNERSHIP, BY TYPE, 2024–2025 (MILLION) 50 FIGURE 13 US: PET INDUSTRY EXPENDITURE, 2016–2025 (USD BILLION) 50 FIGURE 14 VETERINARY VACCINES MARKET: PORTER’S FIVE FORCES ANALYSIS 64 FIGURE 15 VETERINARY VACCINES MARKET: SUPPLY CHAIN ANALYSIS 68 FIGURE 16 VETERINARY VACCINES MARKET: VALUE CHAIN ANALYSIS 69 FIGURE 17 VETERINARY VACCINES MARKET ECOSYSTEM 71 FIGURE 18 AVERAGE SELLING PRICE OF VETERINARY VACCINES, BY KEY PLAYER, 2025 (USD) 75 FIGURE 19 AVERAGE SELLING PRICE OF CANINE VACCINES, BY REGION, 2025 (USD) 77 FIGURE 20 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 81 FIGURE 21 INVESTMENT & FUNDING SCENARIO 82 FIGURE 22 TOP APPLICANTS/OWNERS (COMPANIES/INSTITUTIONS) FOR VETERINARY VACCINES PATENTS, JANUARY 2015–MAY 2026 93 FIGURE 23 VETERINARY VACCINES MARKET: AI USE CASES 100 FIGURE 24 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF VETERINARY VACCINES 109 FIGURE 25 KEY BUYING CRITERIA FOR VETERINARY VACCINES, BY END USER 110 FIGURE 26 NORTH AMERICA: VETERINARY VACCINES MARKET SNAPSHOT 184 FIGURE 27 ASIA PACIFIC: VETERINARY VACCINES MARKET SNAPSHOT 233 FIGURE 28 REVENUE ANALYSIS OF KEY PLAYERS IN VETERINARY VACCINES MARKET, 2023–2025 313 FIGURE 29 GLOBAL MARKET SHARE ANALYSIS OF KEY PLAYERS IN VETERINARY VACCINES MARKET, 2025 314 FIGURE 30 VETERINARY VACCINES MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025 317 FIGURE 31 VETERINARY VACCINES MARKET: COMPANY FOOTPRINT 318 FIGURE 32 VETERINARY VACCINES MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025 325 FIGURE 33 EV/EBITDA OF KEY VENDORS FOR VETERINARY VACCINES 328 FIGURE 34 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS FOR VETERINARY VACCINES 328 FIGURE 35 VETERINARY VACCINES MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS 329 FIGURE 36 MERCK & CO., INC.: COMPANY SNAPSHOT (2025) 334 FIGURE 37 ZOETIS SERVICES LLC: COMPANY SNAPSHOT (2025) 341 FIGURE 38 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY SNAPSHOT (2025) 346 FIGURE 39 ELANCO: COMPANY SNAPSHOT (2025) 350 FIGURE 40 VIRBAC: COMPANY SNAPSHOT (2025) 355 FIGURE 41 PHIBRO ANIMAL HEALTH CORPORATION: COMPANY SNAPSHOT (2025) 364 FIGURE 42 HESTER BIOSCIENCS LIMITED: COMPANY SNAPSHOT (2025) 367 FIGURE 43 NEOGEN CORPORATION: COMPANY SNAPSHOT (2025) 371 FIGURE 44 TIANJIN RINGPU BIO-TECHNOLOGY CO., LTD.: COMPANY SNAPSHOT (2025) 379 FIGURE 45 VETERINARY VACCINE MARKET: RESEARCH DESIGN 401 FIGURE 46 PRIMARY SOURCES 404 FIGURE 47 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS 406 FIGURE 48 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 406 FIGURE 49 BREAKDOWN OF PRIMARY INTERVIEWS: DEMAND-SIDE PARTICIPANTS 407 FIGURE 50 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING 408 FIGURE 51 MARKET SIZE APPROACH: REVENUE SHARE ANALYSIS 409 FIGURE 52 REVENUE SHARE ANALYSIS ILLUSTRATION: MERCK & CO., INC. (2025) 410 FIGURE 53 BOTTOM-UP APPROACH 411 FIGURE 54 TOP-DOWN APPROACH 411 FIGURE 55 DEMAND-SIDE APPROACH 414 FIGURE 56 VETERINARY VACCINES MARKET: CAGR PROJECTION FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES (2026–2031) 415 FIGURE 57 CAGR PROJECTION: SUPPLY-SIDE ANALYSIS 415 FIGURE 58 MARKET DATA TRIANGULATION METHODOLOGY 417